Last week, two of the biggest and oldest companies in the burgeoning AI drug discovery space announced a surprise merger. In a roughly 75-25 deal, Recursion Bio and Exscientia will (if the merger goes ...

How Recursion is leading a new era of AI-driven drug discovery AI drug discovery is not a new phenomenon – but it is evolving at an almost dizzying pace. Recursion is one of the earliest innovators in ...

In early December 2025, Recursion Pharmaceuticals released clinical data from the TUPELO Phase 1b/2 trial of REC-4881, providing fresh insight into the candidate’s safety and efficacy profile. This ...

Recursion Pharmaceuticals, Inc. remains a Sell as pipeline progress, notably REC-4881 in FAP, fails to surpass cheap alternatives like Celebrex. REC-4881's Phase 1/2 data show a median polyp reduction ...

After twelve years at the helm of AI-drug developer Recursion, Chris Gibson will hand the CEO baton to Najat Khan, PhD, the company’s chief R&D officer and chief commercial officer, effective January ...

DNA Ginkgo Bioworks Holdings, Inc.

So far, running LLMs has required a large amount of computing resources, mainly GPUs. Running locally, a simple prompt with a typical LLM takes on an average Mac ...

On par with many of my repositories, this one didn’t start off with great ambition either. It was merely an archive of LeetCode problems and solutions. For a problem like edit distance, there are two ...

Abstract: Cooperative co-evolution (CC) is an efficient and practical evolutionary framework for solving large-scale optimization problems. The performance of CC is affected by the variable ...

Abstract: I welcome you to the fourth issue of the IEEE Communications Surveys and Tutorials in 2021. This issue includes 23 papers covering different aspects of communication networks. In particular, ...